Antipsychotic polypharmacy in USA

Polypharmacy in Psychiatry Practice Volume II: Use of Polypharmacy in the "real world"

Volumn , Issue , 2013, Pages 11-29

  Pandurangi, Anand K ^a,b   Vernon, J T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Schizophrenia Program and Brain Stimulation Therapies Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956561530     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5799-8_2     Document Type: Chapter

References (59)

1. IMS Institute for Healthcare Informatics (2010) The use of medicines in the United States: review of 2010, Parsippany, New Jersey
2. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26
3. Lopez de Torre A, Lertxundi U, Hernandez R, Medrano J (2012) Antipsychotic polypharmacy: a needle in a haystack? Gen Hosp Psychiatry 34(4):423-432, Epub 2012 Mar 27. PMID: 22460003
4. Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ (2007) Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 29(1):183-195
5. Dolder CR, McKinsey J (2011) Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. J Psychiatr Pract 17(5):368-374
6. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443-457
7. Dussias P, Kalali AH, Citrome L (2010) Polypharmacy of schizophrenia. Psychiatry (Edgmont) 7(8): 17-19
8. Sheppard C, Beyel V, Fracchia J, Merlis S (1974) Polypharmacy in psychiatry: a multi-state comparison of psychotropic drug combinations. Dis Nerv Syst 35(4):183-189
9. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68(11):1751-1762
10. American Psychiatric Association (2004) Practice guidelines for the treatment of patients with schizophrenia. American Psychiatric Press, Arlington
11. Gibson A, Patel NC, Lauriello J, Buckley P (2008) Anti-psychotic combinations: blind step or logical? Curr Psychiatry 7:41-48
12. Goff DC, Dixon L (2011) Antipsychotic polypharmacy: are two ever better than one? Am J Psychiatry 168(7):667-669
13. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH (2011) Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168(7):702-708, Epub 2011 May 2. PMID:21536693
14. Preskorn SH, Lacey RL (2007) Polypharmacy: when is it rational? J Psychiatr Pract 13(2):97-105
15. Ereshefsky L (1999) Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60(Suppl 10):20-30, PMID:10340684
16. Stahl SM, Grady MM (2006) High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv 57(1):127-129
17. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138(1):18-28, Epub 2012 Apr 24
18. Eisen C, Shaner R, Unutzer J, Fink A, Wells KB (2008) Datapoints: second-generation antipsychotic medication combinations for schizophrenia. Psychiatr Serv 59(3):235
19. Weissman EM (2002) Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 28(1):31-42
20. Leslie DL, Rosenheck RA (2001) Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 39(9):923-933
21. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65(10):1377-1388
22. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD (1999) Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37(4 Suppl Lilly):AS81-AS86, PMID:10217396
23. Covell NH, Jackson CT, Evans AC, Essock SM (2002) Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28(1):17-29
24. Botts S, Hines H, Littrell R (2003) Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv 54(8):1086
25. Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G (2009) Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Curr Med Res Opin 25(3):755-764
26. Lee B, Walker V (2008) Polypharmacy as the initial second-generation antipsychotic treatment. Psychiatr Serv 59(7):717, PMID:18586985
27. Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM (2011) Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. J Clin Psychiatry 72(8):1079-1085, Epub 2010 Oct 19. PMID: 21034690
28. Aggarwal NK, Sernyak MJ (2012) Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol 32(3):323-328
29. Citrome L, Guo Z, Kalsekar I, Forbes RA, Hebden T (2012) Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot. Innov Clin Neurosci 9(3):17-18
30. Dosreis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A (2011) Antipsychotic treatment among youth in foster care. Pediatrics 128(6):e1459-e1466
31. Constantine RJ, Boaz T, Tandon R (2010) Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 32(5):949-959
32. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30(2):193-217
33. West JC, Wilk JE, Olfson M, Rae DS, Marcus S, Narrow WE, Pincus HA, Regier DA (2005) Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 56(3):283-291
34. The Joint Commission (2008) http://www.jointcommission.org/assets/1718/HBIPS_CM_ selection_form_revised082408.pdf. Retrieved 07 July 2012
35. Moore TA (2011) Schizophrenia treatment guidelines in the United States. Clin Schizophr Relat Psychoses 5(1):40-49, Review
36. Biancosino B, Barbui C, Marmai L, Dona S, Grassi L (2005) Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 20(6):305-309
37. Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ (2006) Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 57(1):21-23
38. Correll CU, Shaikh L, Gallego JA, Nachbar J, Olshanskiy V, Kishimoto T, Kane JM (2011) Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 131(1-3):58-62, Epub 2011 Mar 21. PMID: 21419603
39. Baandrup L (2011) How dosing might influence the conclusion in an antipsychotic polypharmacy effectiveness trial. Am J Psychiatry 168(10):1117, author reply 1117. No abstract available. PMID: 21969048
40. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383-399. doi:10.2165/11587810-000000000-00000
41. Sernyak MJ, Rosenheck R (2004) Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry 65(12):1597-1600
42. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106(5):323-330
43. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162(1):130-136
44. Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics: ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 19(7):520-532
45. Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345-367
46. Avari J, Mahgoub N, Alexopoulos GS (2011) Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report. J Clin Psychopharmacol 31(4):528-531
47. Reinstein MJ, Sirotovskaya LA, Jones LA (1999) Effect of clozapine - quetiapine combination on weight and glycaemic control. Preliminary findings. Clin Drug Invest 18:99-104
48. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC (2009) Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29(2):165-169, PMID: 19512978
49. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115-1125, Epub 2010 May 12. PMID:20459883
50. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164(9):1404-1410
51. Li C, Mittal D, Owen RR (2011) Impact of patients’ preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians. Psychiatr Serv 62(12):1477-1484
52. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122-127
53. Khan A (2010) Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy. Evid Based Ment Health 13(3):90, No abstract available. PMID: 20682830
54. Finnerty MT, Kealey E, Leckman-Westin E, Gupta N, White TM, Engel GM, Opler LA (2011) Psychiatric Services and Clinical Knowledge Enhancement System initiated in 3 phases in NYSOMH network of 18 psychiatric hospitals Long-term impact of web-based tools, leadership feedback, and policies on inpatient antipsychotic polypharmacy. Psychiatr Serv 62(10): 1124-1126
55. Goren JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann RC (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571-582, Review. PMID:18947117
56. Constantine RJ, Andel R, Tandon R (2010) Trends in adult antipsychotic polypharmacy: progress and challenges in Florida’s Medicaid program. Community Ment Health J 46(6):523-530, Epub 2010 Jan 23. PMID:20099030
57. Zuvekas SH, Rupp AE, Norquist GS (2005) Spillover effects of benefit expansions and carve-outs on psychotropic medication use and costs. Inquiry 42(1):86-97
58. Aparasu RR, Bhatara V (2006) Antipsychotic use and expenditure in the United States. Psychiatr Serv 57(12):1693
59. Valuck RJ, Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R (2007) Medicaid Pharmacotherapy Research Consortium: how expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Curr Med Res Opin 23(10):2567-2576